JP2017505762A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505762A5 JP2017505762A5 JP2016542692A JP2016542692A JP2017505762A5 JP 2017505762 A5 JP2017505762 A5 JP 2017505762A5 JP 2016542692 A JP2016542692 A JP 2016542692A JP 2016542692 A JP2016542692 A JP 2016542692A JP 2017505762 A5 JP2017505762 A5 JP 2017505762A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- methyl
- substituted
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 99
- 229910052739 hydrogen Inorganic materials 0.000 claims 59
- 239000001257 hydrogen Substances 0.000 claims 59
- 150000002431 hydrogen Chemical class 0.000 claims 52
- 125000001072 heteroaryl group Chemical group 0.000 claims 42
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 37
- 125000000623 heterocyclic group Chemical group 0.000 claims 30
- 229910052736 halogen Inorganic materials 0.000 claims 29
- 150000002367 halogens Chemical class 0.000 claims 29
- -1 CD 3 Chemical class 0.000 claims 28
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 25
- 125000003107 substituted aryl group Chemical group 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 17
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 16
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- 238000006243 chemical reaction Methods 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 108091005625 BRD4 Proteins 0.000 claims 3
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 229940125763 bromodomain inhibitor Drugs 0.000 claims 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 102000001805 Bromodomains Human genes 0.000 claims 2
- 108050009021 Bromodomains Proteins 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- BPCOFZMFXLWUCE-XDFJSJKPSA-N (1R)-1-cyclopropyl-1-[3-(3,5-dimethyltriazol-4-yl)-6-fluoro-5-[(S)-(2-fluorophenyl)-(oxan-4-yl)methyl]pyrido[3,2-b]indol-7-yl]ethanol Chemical compound C1(CC1)[C@@](C)(O)C=1C=CC=2C3=C(N(C=2C=1F)[C@@H](C1CCOCC1)C1=C(C=CC=C1)F)C=C(C=N3)C1=C(N=NN1C)C BPCOFZMFXLWUCE-XDFJSJKPSA-N 0.000 claims 1
- MSEKYFJKNKKJIR-QMGDAUJMSA-N (1R)-1-cyclopropyl-1-[6-fluoro-3-[3-methyl-5-(trideuteriomethyl)triazol-4-yl]-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]ethanol Chemical compound C1(CC1)[C@@](C)(O)C=1C=CC=2C3=C(N(C=2C=1F)[C@H](C1=CC=CC=C1)C1CCOCC1)C=C(C=N3)C1=C(N=NN1C)C([2H])([2H])[2H] MSEKYFJKNKKJIR-QMGDAUJMSA-N 0.000 claims 1
- BPCOFZMFXLWUCE-MDSYIZKJSA-N (1R)-1-cyclopropyl-1-[6-fluoro-5-[(S)-(2-fluorophenyl)-(oxan-4-yl)methyl]-3-[3-methyl-5-(trideuteriomethyl)triazol-4-yl]pyrido[3,2-b]indol-7-yl]ethanol Chemical compound C1(CC1)[C@@](C)(O)C=1C=CC=2C3=C(N(C=2C=1F)[C@@H](C1CCOCC1)C1=C(C=CC=C1)F)C=C(C=N3)C1=C(N=NN1C)C([2H])([2H])[2H] BPCOFZMFXLWUCE-MDSYIZKJSA-N 0.000 claims 1
- MSEKYFJKNKKJIR-CEKGIIEHSA-N (1S)-1-cyclopropyl-1-[6-fluoro-3-[3-methyl-5-(trideuteriomethyl)triazol-4-yl]-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]ethanol Chemical compound C1(CC1)[C@](C)(O)C=1C=CC=2C3=C(N(C=2C=1F)[C@H](C1=CC=CC=C1)C1CCOCC1)C=C(C=N3)C1=C(N=NN1C)C([2H])([2H])[2H] MSEKYFJKNKKJIR-CEKGIIEHSA-N 0.000 claims 1
- SSJXIUAHEKJCMH-WDSKDSINSA-N (1s,2s)-cyclohexane-1,2-diamine Chemical compound N[C@H]1CCCC[C@@H]1N SSJXIUAHEKJCMH-WDSKDSINSA-N 0.000 claims 1
- JZTHYZIZUIOGKF-SSEXGKCCSA-N 2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-[(S)-(4-fluorophenyl)-(oxan-4-yl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-ol Chemical compound CC1=C(C(=NO1)C)C1=CC=2N(C=3C=C(C=CC=3C=2N=C1)C(C)(C)O)[C@@H](C1CCOCC1)C1=CC=C(C=C1)F JZTHYZIZUIOGKF-SSEXGKCCSA-N 0.000 claims 1
- LZAPXWCSDTYFNB-SSEXGKCCSA-N 2-[3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-ol Chemical compound CC1=C(C(=NO1)C)C1=CC=2N(C=3C=C(C=CC=3C=2N=C1)C(C)(C)O)[C@H](C1=CC=CC=C1)C1CCOCC1 LZAPXWCSDTYFNB-SSEXGKCCSA-N 0.000 claims 1
- BTZFFGCZYGLTFW-UHFFFAOYSA-N 2-[3-(3,5-dimethyltriazol-4-yl)-5-(1,1,1,7,7,7-hexafluoroheptan-4-yl)pyrido[3,2-b]indol-7-yl]propan-2-ol Chemical compound CC=1N=NN(C=1C1=CC=2N(C=3C=C(C=CC=3C=2N=C1)C(C)(C)O)C(CCC(F)(F)F)CCC(F)(F)F)C BTZFFGCZYGLTFW-UHFFFAOYSA-N 0.000 claims 1
- RURNTLSPMSYZJR-QFIPXVFZSA-N 2-[3-(3,5-dimethyltriazol-4-yl)-5-[(1S)-4,4,4-trifluoro-1-phenylbutyl]pyrido[3,2-b]indol-7-yl]propan-2-ol Chemical compound CC=1N=NN(C=1C1=CC=2N(C=3C=C(C=CC=3C=2N=C1)C(C)(C)O)[C@@H](CCC(F)(F)F)C1=CC=CC=C1)C RURNTLSPMSYZJR-QFIPXVFZSA-N 0.000 claims 1
- KGERZPVQIRYWRK-GDLZYMKVSA-N 2-[3-(3,5-dimethyltriazol-4-yl)-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-ol Chemical compound CC=1N=NN(C=1C1=CC=2N(C=3C=C(C=CC=3C=2N=C1)C(C)(C)O)[C@H](C1=CC=CC=C1)C1CCOCC1)C KGERZPVQIRYWRK-GDLZYMKVSA-N 0.000 claims 1
- UWIXBDZWGJDKJL-MUUNZHRXSA-N 2-[3-(3,5-dimethyltriazol-4-yl)-6-fluoro-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-amine Chemical compound CC=1N=NN(C=1C1=CC=2N(C=3C(=C(C=CC=3C=2N=C1)C(C)(C)N)F)[C@H](C1=CC=CC=C1)C1CCOCC1)C UWIXBDZWGJDKJL-MUUNZHRXSA-N 0.000 claims 1
- OYOOOLZFBKNGEJ-MUUNZHRXSA-N 2-[3-(3,5-dimethyltriazol-4-yl)-6-fluoro-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-ol Chemical compound CC=1N=NN(C=1C1=CC=2N(C=3C(=C(C=CC=3C=2N=C1)C(C)(C)O)F)[C@H](C1=CC=CC=C1)C1CCOCC1)C OYOOOLZFBKNGEJ-MUUNZHRXSA-N 0.000 claims 1
- FUDZXYQEMRWJGN-HHHXNRCGSA-N 2-[3-(5-methoxy-3-methyltriazol-4-yl)-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-ol Chemical compound COC=1N=NN(C=1C1=CC=2N(C=3C=C(C=CC=3C=2N=C1)C(C)(C)O)[C@H](C1=CC=CC=C1)C1CCOCC1)C FUDZXYQEMRWJGN-HHHXNRCGSA-N 0.000 claims 1
- KGERZPVQIRYWRK-GNUZTRDVSA-N 2-[3-[3-methyl-5-(trideuteriomethyl)triazol-4-yl]-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-ol Chemical compound C(C=1N=NN(C=1C1=CC=2N(C=3C=C(C=CC=3C=2N=C1)C(C)(C)O)[C@H](C1=CC=CC=C1)C1CCOCC1)C)([2H])([2H])[2H] KGERZPVQIRYWRK-GNUZTRDVSA-N 0.000 claims 1
- RMQALCZQOUJTEN-MUUNZHRXSA-N 2-[3-[5-(hydroxymethyl)-3-methyltriazol-4-yl]-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-ol Chemical compound OCC=1N=NN(C=1C1=CC=2N(C=3C=C(C=CC=3C=2N=C1)C(C)(C)O)[C@H](C1=CC=CC=C1)C1CCOCC1)C RMQALCZQOUJTEN-MUUNZHRXSA-N 0.000 claims 1
- DVGOMSURZGWXJT-GNUZTRDVSA-N 2-[5-[(S)-(4,4-difluorocyclohexyl)-phenylmethyl]-3-[3-methyl-5-(trideuteriomethyl)triazol-4-yl]pyrido[3,2-b]indol-7-yl]propan-2-ol Chemical compound FC1(CCC(CC1)[C@H](N1C2=C(C=3C=CC(=CC1=3)C(C)(C)O)N=CC(=C2)C1=C(N=NN1C)C([2H])([2H])[2H])C1=CC=CC=C1)F DVGOMSURZGWXJT-GNUZTRDVSA-N 0.000 claims 1
- PUHMOBALEOWSMA-HHHXNRCGSA-N 3-(3,5-dimethyltriazol-4-yl)-6-methylsulfonyl-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indole Chemical compound CS(=O)(=O)C1=CC=CC=2C3=C(N(C1=2)[C@H](C1=CC=CC=C1)C1CCOCC1)C=C(C=N3)C1=C(N=NN1C)C PUHMOBALEOWSMA-HHHXNRCGSA-N 0.000 claims 1
- WMGCUONRPGLRCM-GDLZYMKVSA-N 3-(3,5-dimethyltriazol-4-yl)-7-(methylsulfonylmethyl)-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indole Chemical compound Cc1nnn(C)c1-c1cnc2c(c1)n([C@@H](C1CCOCC1)c1ccccc1)c1cc(CS(C)(=O)=O)ccc21 WMGCUONRPGLRCM-GDLZYMKVSA-N 0.000 claims 1
- NWGRIRJJSNFTFM-MUUNZHRXSA-N 3-(3,5-dimethyltriazol-4-yl)-9-methoxy-6-methylsulfonyl-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indole Chemical compound CS(=O)(=O)C1=CC=C(C=2C3=C(N(C1=2)[C@H](C1=CC=CC=C1)C1CCOCC1)C=C(C=N3)C1=C(N=NN1C)C)OC NWGRIRJJSNFTFM-MUUNZHRXSA-N 0.000 claims 1
- HQGZYVXIERSSDA-MUUNZHRXSA-N 3-(3,5-dimethyltriazol-4-yl)-9-methylsulfonyl-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indole Chemical compound CS(=O)(=O)C=1C=2C3=C(N(C=2C=CC=1)[C@H](C1=CC=CC=C1)C1CCOCC1)C=C(C=N3)C1=C(N=NN1C)C HQGZYVXIERSSDA-MUUNZHRXSA-N 0.000 claims 1
- RLXUBJLRVMWJTK-AREMUKBSSA-N 3-(5-methoxy-3-methyltriazol-4-yl)-7-methylsulfonyl-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indole Chemical compound CS(=O)(=O)C=1C=CC=2C3=C(N(C=2C=1)[C@H](C1=CC=CC=C1)C1CCOCC1)C=C(C=N3)C1=C(N=NN1C)OC RLXUBJLRVMWJTK-AREMUKBSSA-N 0.000 claims 1
- YJMAADZMFJXYOJ-MZHKYADFSA-N 5-[(R)-(4,4-difluorocyclohexyl)-(3-fluoropyridin-2-yl)methyl]-9-fluoro-7-methylsulfonyl-3-[3-methyl-5-(trideuteriomethyl)triazol-4-yl]pyrido[3,2-b]indole Chemical compound FC1(CCC(CC1)[C@H](C1=NC=CC=C1F)N1C2=C(C=3C(=CC(=CC1=3)S(=O)(=O)C)F)N=CC(=C2)C1=C(N=NN1C)C([2H])([2H])[2H])F YJMAADZMFJXYOJ-MZHKYADFSA-N 0.000 claims 1
- UJSHFOHIUINCFM-MLBVKCQFSA-N 5-[(S)-(4-fluorophenyl)-(oxan-4-yl)methyl]-7-methylsulfonyl-3-[3-methyl-5-(trideuteriomethyl)triazol-4-yl]pyrido[3,2-b]indole Chemical compound FC1=CC=C(C=C1)[C@@H](N1C2=C(C=3C=CC(=CC1=3)S(=O)(=O)C)N=CC(=C2)C1=C(N=NN1C)C([2H])([2H])[2H])C1CCOCC1 UJSHFOHIUINCFM-MLBVKCQFSA-N 0.000 claims 1
- GGUNMQZRJAUVAP-MLBVKCQFSA-N 9-fluoro-7-methylsulfonyl-3-[3-methyl-5-(trideuteriomethyl)triazol-4-yl]-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indole Chemical compound [2H]C([2H])([2H])C1=C(N(C)N=N1)C1=CC2=C(N=C1)C1=C(F)C=C(C=C1N2[C@@H](C1CCOCC1)C1=CC=CC=C1)S(C)(=O)=O GGUNMQZRJAUVAP-MLBVKCQFSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- VPTJTZKWJIHVPF-SSEXGKCCSA-N N-[2-[3-(3,5-dimethyltriazol-4-yl)-6-fluoro-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-yl]acetamide Chemical compound CC=1N=NN(C=1C1=CC=2N(C=3C(=C(C=CC=3C=2N=C1)C(C)(C)NC(C)=O)F)[C@H](C1=CC=CC=C1)C1CCOCC1)C VPTJTZKWJIHVPF-SSEXGKCCSA-N 0.000 claims 1
- UIWQTEYTWQYNMF-GDLZYMKVSA-N N-[2-[3-(3,5-dimethyltriazol-4-yl)-6-fluoro-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-yl]methanesulfonamide Chemical compound CC=1N=NN(C=1C1=CC=2N(C=3C(=C(C=CC=3C=2N=C1)C(C)(C)NS(=O)(=O)C)F)[C@H](C1=CC=CC=C1)C1CCOCC1)C UIWQTEYTWQYNMF-GDLZYMKVSA-N 0.000 claims 1
- UBWXNTKYRHDOQL-SSEXGKCCSA-N N-[3-(3,5-dimethyltriazol-4-yl)-6-methylsulfonyl-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-9-yl]cyclopropanesulfonamide Chemical compound CC=1N=NN(C=1C1=CC=2N(C=3C(=CC=C(C=3C=2N=C1)NS(=O)(=O)C1CC1)S(=O)(=O)C)[C@H](C1=CC=CC=C1)C1CCOCC1)C UBWXNTKYRHDOQL-SSEXGKCCSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- WDHSXBMZTHNROU-GDLZYMKVSA-N methyl N-[2-[3-(3,5-dimethyltriazol-4-yl)-6-fluoro-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-yl]carbamate Chemical compound CC=1N=NN(C=1C1=CC=2N(C=3C(=C(C=CC=3C=2N=C1)C(C)(C)NC(OC)=O)F)[C@H](C1=CC=CC=C1)C1CCOCC1)C WDHSXBMZTHNROU-GDLZYMKVSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 *c1c[n](*)nc1 Chemical compound *c1c[n](*)nc1 0.000 description 16
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920500P | 2013-12-24 | 2013-12-24 | |
| US61/920,500 | 2013-12-24 | ||
| PCT/US2014/072031 WO2015100282A1 (en) | 2013-12-24 | 2014-12-23 | Tricyclic compounds as anticancer agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019002078A Division JP6675501B2 (ja) | 2013-12-24 | 2019-01-09 | 抗がん剤としての三環式化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017505762A JP2017505762A (ja) | 2017-02-23 |
| JP2017505762A5 true JP2017505762A5 (enExample) | 2017-12-21 |
| JP6466456B2 JP6466456B2 (ja) | 2019-02-06 |
Family
ID=52293305
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542692A Active JP6466456B2 (ja) | 2013-12-24 | 2014-12-23 | 抗がん剤としての三環式化合物 |
| JP2019002078A Active JP6675501B2 (ja) | 2013-12-24 | 2019-01-09 | 抗がん剤としての三環式化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019002078A Active JP6675501B2 (ja) | 2013-12-24 | 2019-01-09 | 抗がん剤としての三環式化合物 |
Country Status (34)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6404838B2 (ja) | 2013-02-27 | 2018-10-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ブロモドメイン阻害剤として有用なカルバゾール化合物 |
| KR20160072261A (ko) | 2013-11-08 | 2016-06-22 | 다나-파버 캔서 인스티튜트 인크. | 브로모도메인 및 엑스트라-말단 (bet) 단백질 저해제를 이용한 암 치료를 위한 조합 요법 |
| DK3466949T3 (da) * | 2013-12-24 | 2021-03-15 | Bristol Myers Squibb Co | Tricyklisk forbindelse som anticancermidler |
| US9458156B2 (en) | 2014-12-23 | 2016-10-04 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| US9580430B2 (en) * | 2014-02-28 | 2017-02-28 | The Regents Of The University Of Michigan | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors |
| ES2770349T3 (es) | 2015-05-12 | 2020-07-01 | Bristol Myers Squibb Co | Compuestos de 5H-pirido[3,2-b]indol como agentes antineoplásicos |
| US9725449B2 (en) | 2015-05-12 | 2017-08-08 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| CN116059219A (zh) * | 2015-07-16 | 2023-05-05 | 比奥克斯塞尔医疗股份有限公司 | 一种使用免疫调节治疗癌症的新颖方法 |
| PE20181068A1 (es) * | 2015-10-02 | 2018-07-04 | Dana Farber Cancer Inst Inc | Terapia de combinacion de inhibidores de bromodominios y bloqueo de puntos de control |
| WO2017124934A1 (zh) * | 2016-01-20 | 2017-07-27 | 宁波文达医药科技有限公司 | 作为布罗莫区结构域抑制剂的含膦咔啉衍生物 |
| JP6855505B2 (ja) * | 2016-01-20 | 2021-04-07 | ニンボー ウェンダ ファーマー テクノロジー エルティーディー． | ブロモドメイン阻害剤としてのカルボリン誘導体 |
| EP3412669A4 (en) * | 2016-02-05 | 2019-09-04 | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd | TRICYCLIC COMPOUND FOR PROTEIN INHIBITOR CONTAINING BROMODOMAINE AND PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| JP6847120B2 (ja) | 2016-03-01 | 2021-03-24 | コーセプト セラピューティクス， インコーポレイテッド | チェックポイントインヒビターを強化するためのグルココルチコイドレセプターモジュレーターの使用 |
| US10150754B2 (en) * | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| JP2019534306A (ja) | 2016-11-10 | 2019-11-28 | 羅欣薬業（上海）有限公司Ｌｕｏｘｉｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ（Ｓｈａｎｇｈａｉ） Ｃｏ．， Ｌｔｄ． | 窒素含有大員環系化合物、その製造方法、薬物組成物および使用 |
| CN109824693B (zh) * | 2017-04-18 | 2020-12-08 | 四川大学 | Brd4抑制剂及其在肿瘤治疗药物中的应用 |
| CN111356695B (zh) * | 2017-10-27 | 2022-12-30 | 北京加科思新药研发有限公司 | 新的三环化合物 |
| CA3104927C (en) | 2018-06-25 | 2023-09-12 | Jacobio Pharmaceuticals Co., Ltd. | Tricyclic compounds |
| CN108840868B (zh) * | 2018-08-01 | 2019-10-18 | 上海山的实业有限公司 | 具有抗肿瘤活性的吲哚并吡啶酮类化合物的制备方法及应用 |
| WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| WO2020200284A1 (zh) * | 2019-04-04 | 2020-10-08 | 上海华汇拓医药科技有限公司 | 三环类化合物制备方法及其在医药领域的应用 |
| CN110003204B (zh) * | 2019-04-30 | 2020-08-11 | 上海勋和医药科技有限公司 | 一种bet蛋白抑制剂、其制备方法及用途 |
| US10947253B2 (en) | 2019-08-05 | 2021-03-16 | Ankh Life Sciences Limited | Fused polycyclic dimers |
| WO2021065980A1 (ja) | 2019-09-30 | 2021-04-08 | 協和キリン株式会社 | Ｂｅｔ分解剤 |
| US12129265B2 (en) | 2020-07-21 | 2024-10-29 | Ankh Life Sciences Limited | Therapeutic agents and uses thereof |
| AU2022211285A1 (en) * | 2021-01-22 | 2023-08-17 | Jingrui Biopharma Co., Ltd. | Tricyclic compounds as anticancer agents |
| KR20230148208A (ko) * | 2021-02-25 | 2023-10-24 | 임팩트 바이오메디신스, 인코포레이티드 | 골수섬유증과 같은 혈액 악성종양을 치료하기 위한 bet 억제제 단독 또는 페드라티닙 또는 룩솔리티닙과의 조합물의 용도 |
| US12016847B2 (en) * | 2021-03-12 | 2024-06-25 | Bristol-Myers Squibb Company | Methods of treating prostate cancer |
| CN117881659A (zh) * | 2021-05-06 | 2024-04-12 | 拉结尔治疗有限公司 | 结晶咔唑衍生物 |
| WO2024099441A1 (en) * | 2022-11-11 | 2024-05-16 | Jingrui Biopharma (Shandong) Co., Ltd. | Bromodomain and extra-terminal (bet) protein degrader |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993014080A1 (en) * | 1992-01-15 | 1993-07-22 | E.I. Du Pont De Nemours And Company | Bridged heterocyclic fungicides |
| WO2005039569A1 (en) | 2003-10-18 | 2005-05-06 | Bayer Healthcare Ag | 5-substituted 2-(phenylmethyl) thio-4-phenyl-4h-1,2,4-triazole derivatives and related compounds as gaba-agonists for the treatment of urinary incontinence and related diseases |
| EP1686949A2 (en) * | 2003-11-24 | 2006-08-09 | Viropharma Incorporated | Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| WO2006105021A2 (en) | 2005-03-25 | 2006-10-05 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
| GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| RS52711B (sr) | 2005-05-10 | 2013-08-30 | Incyte Corporation | Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| EP1971583B1 (en) | 2005-12-20 | 2015-03-25 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| CA2693677C (en) | 2007-07-12 | 2018-02-13 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| EP2227233B1 (en) | 2007-11-30 | 2013-02-13 | Newlink Genetics | Ido inhibitors |
| FR2927330B1 (fr) | 2008-02-07 | 2010-02-19 | Sanofi Aventis | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| CN102325752B (zh) * | 2008-12-19 | 2015-02-04 | 百时美施贵宝公司 | 咔唑和咔啉激酶抑制剂 |
| RU2595409C2 (ru) | 2009-09-03 | 2016-08-27 | Мерк Шарп И Доум Корп., | Анти-gitr-антитела |
| WO2011056652A1 (en) | 2009-10-28 | 2011-05-12 | Newlink Genetics | Imidazole derivatives as ido inhibitors |
| AU2010329934B2 (en) | 2009-12-10 | 2015-05-14 | F. Hoffmann-La Roche Ag | Antibodies binding preferentially human CSF1R extracellular domain 4 and their use |
| PH12012501693A1 (en) | 2010-02-26 | 2012-11-05 | Boehringer Ingelheim Int | 4 - [cycloalkyloxy (hetero) arylamino] thieno [2,3 - d] pyrimidines having mnkl/mnk2 inhibiting activity for pharmaceutical compositions |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| MX2012010014A (es) | 2010-03-05 | 2012-09-21 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| CA2789071C (en) | 2010-03-05 | 2018-03-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| TWI503323B (zh) * | 2010-03-29 | 2015-10-11 | Oncotherapy Science Inc | 三環化合物以及含此化合物之ｐｂｋ抑制劑 |
| MX355418B (es) | 2010-05-04 | 2018-04-18 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| JP5860042B2 (ja) | 2010-06-16 | 2016-02-16 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | 置換５、６及び７員複素環、そのような化合物を含有する医薬及びそれらの使用 |
| CN103221428B (zh) | 2010-09-09 | 2016-02-10 | 辉瑞公司 | 4-1bb结合分子 |
| CA2820078C (en) * | 2010-12-16 | 2019-02-12 | F. Hoffmann-La Roche Ag | Tricyclic pi3k inhibitor compounds and methods of use |
| US8580399B2 (en) * | 2011-04-08 | 2013-11-12 | Universal Display Corporation | Substituted oligoazacarbazoles for light emitting diodes |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| CN103827109A (zh) * | 2011-09-28 | 2014-05-28 | 出光兴产株式会社 | 有机电致发光元件用材料及使用了该材料的有机电致发光元件 |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| US10023643B2 (en) | 2011-12-15 | 2018-07-17 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
| EP2812355A4 (en) | 2012-02-06 | 2016-03-02 | Hoffmann La Roche | COMPOSITIONS AND METHODS OF USE OF CSF1R INHIBITORS |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| JP2015517490A (ja) | 2012-05-11 | 2015-06-22 | ファイブ プライム セラピューティックス インコーポレイテッド | コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| SG10201906328RA (en) | 2012-08-31 | 2019-08-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| UA115576C2 (uk) * | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| US9492460B2 (en) * | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| JP6404838B2 (ja) * | 2013-02-27 | 2018-10-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ブロモドメイン阻害剤として有用なカルバゾール化合物 |
| EP2970312B1 (en) * | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| DK3466949T3 (da) * | 2013-12-24 | 2021-03-15 | Bristol Myers Squibb Co | Tricyklisk forbindelse som anticancermidler |
-
2014
- 2014-12-23 DK DK18192207.1T patent/DK3466949T3/da active
- 2014-12-23 PE PE2016000945A patent/PE20160844A1/es unknown
- 2014-12-23 PT PT14824743T patent/PT3087071T/pt unknown
- 2014-12-23 PL PL18192207T patent/PL3466949T3/pl unknown
- 2014-12-23 HU HUE14824743A patent/HUE041719T2/hu unknown
- 2014-12-23 WO PCT/US2014/072031 patent/WO2015100282A1/en not_active Ceased
- 2014-12-23 CN CN201480076189.0A patent/CN106029663B/zh active Active
- 2014-12-23 SG SG11201605097SA patent/SG11201605097SA/en unknown
- 2014-12-23 JP JP2016542692A patent/JP6466456B2/ja active Active
- 2014-12-23 NZ NZ72232614A patent/NZ722326A/en not_active IP Right Cessation
- 2014-12-23 SI SI201431748T patent/SI3466949T1/sl unknown
- 2014-12-23 CN CN201810460901.7A patent/CN108558871B/zh active Active
- 2014-12-23 RS RS20210158A patent/RS61479B1/sr unknown
- 2014-12-23 MY MYPI2016702341A patent/MY176489A/en unknown
- 2014-12-23 EA EA201990240A patent/EA201990240A1/ru unknown
- 2014-12-23 SI SI201430891T patent/SI3087071T1/sl unknown
- 2014-12-23 TW TW103145061A patent/TWI736517B/zh active
- 2014-12-23 BR BR112016013744-2A patent/BR112016013744B1/pt active IP Right Grant
- 2014-12-23 MA MA39211A patent/MA39211B1/fr unknown
- 2014-12-23 DK DK14824743.0T patent/DK3087071T3/da active
- 2014-12-23 TW TW108146502A patent/TWI726544B/zh not_active IP Right Cessation
- 2014-12-23 UY UY0001035916A patent/UY35916A/es unknown
- 2014-12-23 RS RS20181319A patent/RS58014B1/sr unknown
- 2014-12-23 LT LTEP18192207.1T patent/LT3466949T/lt unknown
- 2014-12-23 HU HUE18192207A patent/HUE054183T2/hu unknown
- 2014-12-23 EP EP14824743.0A patent/EP3087071B1/en active Active
- 2014-12-23 HR HRP20181849TT patent/HRP20181849T1/hr unknown
- 2014-12-23 KR KR1020167019782A patent/KR102457145B1/ko active Active
- 2014-12-23 ES ES18192207T patent/ES2857848T3/es active Active
- 2014-12-23 AR ARP140104912A patent/AR099379A1/es active IP Right Grant
- 2014-12-23 EP EP18192207.1A patent/EP3466949B1/en active Active
- 2014-12-23 ES ES14824743T patent/ES2698998T3/es active Active
- 2014-12-23 EA EA201691070A patent/EA032469B1/ru not_active IP Right Cessation
- 2014-12-23 US US15/107,652 patent/US20160318928A1/en not_active Abandoned
- 2014-12-23 SM SM20180643T patent/SMT201800643T1/it unknown
- 2014-12-23 CA CA2934953A patent/CA2934953C/en active Active
- 2014-12-23 LT LTEP14824743.0T patent/LT3087071T/lt unknown
- 2014-12-23 PL PL14824743T patent/PL3087071T3/pl unknown
- 2014-12-23 AU AU2014369982A patent/AU2014369982B2/en active Active
- 2014-12-23 TN TN2016000238A patent/TN2016000238A1/en unknown
- 2014-12-23 PT PT181922071T patent/PT3466949T/pt unknown
- 2014-12-23 SM SM20210165T patent/SMT202100165T1/it unknown
- 2014-12-23 MX MX2016007928A patent/MX369491B/es active IP Right Grant
-
2016
- 2016-05-24 PH PH12016500953A patent/PH12016500953A1/en unknown
- 2016-06-20 IL IL246359A patent/IL246359B/en active IP Right Grant
- 2016-06-23 CL CL2016001629A patent/CL2016001629A1/es unknown
-
2018
- 2018-12-04 CY CY181101293T patent/CY1121076T1/el unknown
-
2019
- 2019-01-09 JP JP2019002078A patent/JP6675501B2/ja active Active
-
2021
- 2021-02-08 HR HRP20210212TT patent/HRP20210212T8/hr unknown
- 2021-03-17 CY CY20211100226T patent/CY1124061T1/el unknown
- 2021-11-03 AR ARP210103062A patent/AR123996A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505762A5 (enExample) | ||
| JP2018515525A5 (enExample) | ||
| RU2485114C2 (ru) | Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов | |
| JP2009534386A5 (enExample) | ||
| JP2012532931A5 (enExample) | ||
| JP2016164184A5 (enExample) | ||
| JP2020516671A5 (enExample) | ||
| RU2020112759A (ru) | Гетероциклические соединения в качестве ингибиторов PAD | |
| RU2019132155A (ru) | Ингибиторные соединения | |
| JP2018080173A5 (enExample) | ||
| RU2012134306A (ru) | Азотосодержащие производные гетероарилов | |
| JP2016516043A5 (enExample) | ||
| JP2010533158A5 (enExample) | ||
| IL263511A (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| JP2016515098A5 (enExample) | ||
| JP2017008079A5 (enExample) | ||
| WO2015002754A2 (en) | Novel bicyclic bromodomain inhibitors | |
| RU2010125121A (ru) | Биарилзамещенные производные азабициклических алканов | |
| HRP20230789T1 (hr) | Derivati benzhidroksamske kiseline kao selektivni inhibitori hdac6 | |
| JP2016525075A5 (enExample) | ||
| JP2018524338A5 (enExample) | ||
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| RU2016141645A (ru) | ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ | |
| JP2019504901A5 (enExample) | ||
| JP2019512535A5 (enExample) |